Safety of hormonal contraception among women with liver disease: an updated systematic review. [PDF]
Kapp N +6 more
europepmc +1 more source
ABSTRACT Background Fear of procedural pain is a significant barrier to intrauterine device (IUD) uptake. Non‐steroidal anti‐inflammatory drugs (NSAIDs) are commonly used in IUD insertion for their analgesic and anti‐inflammatory properties; however, evidence for their effectiveness remains inconsistent.
Marita S. Bolic +3 more
wiley +1 more source
Engineering Decavalent, Sperm-Binding Laminin-IgG Hybrid Antibodies for Potent Non-Hormonal Contraception. [PDF]
Schaefer A +8 more
europepmc +1 more source
Estetrol‐based combined oral contraceptives: A systematic review of clinical outcomes
This systematic review summarizes clinical outcomes of estetrol‐containing combined oral contraceptives, showing reliable contraceptive efficacy, predictable bleeding patterns, improved well‐being, and a favorable hemostatic and metabolic profile, suggesting a promising and potentially safer alternative to ethinylestradiol‐based formulations.
Mathilde Råberg +3 more
wiley +1 more source
Hormonal contraception after use of ulipristal acetate as emergency contraception: A systematic review. [PDF]
Snyder EM +6 more
europepmc +1 more source
Cardiovascular Health in Women—Across the Lifespan
ABSTRACT Cardiovascular disease (CVD) remains the leading cause of mortality and morbidity among women worldwide. However, CVD continues to be perceived as a predominantly male issue. CVD in women therefore remains understudied, underrecognized and undertreated.
Jaya Chandrasekhar +5 more
wiley +1 more source
Thrombosis risk with the use of hormonal contraception among women with thrombophilia: An updated systematic review. [PDF]
Tepper NK +5 more
europepmc +1 more source
Use of systemic hormonal contraception and risk of depression: a registry-based study from Finland. [PDF]
Toffol E +5 more
europepmc +1 more source
Abstract Autosomal polycystic kidney disease (ADPKD) is the most common form of inherited kidney disease. The international guideline developer, Kidney Disease: Improving Global Outcomes (KDIGO), published a 2025 clinical practice guideline reflecting advances in genetic testing and the first disease‐modifying agent, tolvaptan.
Mia E. Abdy +26 more
wiley +1 more source
Hormonal Contraception and Endometrial Thickness in IVF/ICSI Cycles: A Multicentre Historical Cohort Study. [PDF]
Michaelsen MP +11 more
europepmc +1 more source

